113 results
Page 4 of 6
8-K
EX-99.1
m9ku9x7s1dz74c94
29 Jun 21
InMed Pharmaceuticals Signs Non-binding Letter of Intent to Acquire BayMedica, a Commercial Manufacturer of Rare Cannabinoids
3:12pm
8-K
EX-99.1
p4nih5im9jihtb
13 May 21
InMed Pharmaceuticals Reports Third Quarter Fiscal 2021 Financial Results
4:23pm
8-K
EX-99.1
pt4jtju 6s4
28 Apr 21
Regulation FD Disclosure
1:31pm
424B3
yfhjws0w4menu
16 Mar 21
Prospectus supplement
12:00am
8-K
EX-99.1
g12hl8mp
12 Feb 21
InMed Pharmaceuticals Reports Second Quarter Fiscal 2021 Financial Results
12:35pm
8-K
EX-10.2
nqmjlxc38tmvd
5 Feb 21
InMed Announces US$4.5 Million Private Placement
5:28pm
8-K
EX-99.1
lyczp okk1jwvb
20 Jan 21
Regulation FD Disclosure
3:43pm
8-K
EX-99.1
4ysdc5mjw6ssf47b68h0
11 Jan 21
Regulation FD Disclosure
6:03am
8-K
EX-99.1
q7slsvx699lr
8 Jan 21
InMed Announces Results of Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects
10:53am
10-Q
ihy7l
17 Dec 20
Quarterly report
12:00am
8-K
EX-99.1
fvd0 vnfazw04i2u
3 Dec 20
Regulation FD Disclosure
12:59pm
8-K
EX-99.1
d96dw u4tq8qi4t13
25 Nov 20
InMed Announces Results of Initial Phase 1 Clinical Trial of INM-755
10:47am
8-K
yvwjb15xe ieayqwi
25 Nov 20
InMed Announces Results of Initial Phase 1 Clinical Trial of INM-755
10:47am
424B4
t5a zo654x3qjepix
13 Nov 20
Prospectus supplement with pricing info
8:52pm
8-K
EX-1.1
fwv3h8
12 Nov 20
InMed Announces Pricing of US$8M Public Offering and
10:15am
UPLOAD
1m2 5bu7s
23 Sep 20
Letter from SEC
12:00am